Skip to main content

Table 1 Baseline demographics and pulmonary functions (mean ± SD) of 45 asthmatic patients

From: Sulforaphane improves the bronchoprotective response in asthmatics through Nrf2-mediated gene pathways

  Non-smoker Smoker All
Number of subjects (n) 30 15 45
Male/female 10/20 9/6 19/26
Age (mean ± SD) 38 ± 14 40 ± 13 38 ± 13
Smoking (pack-years) 0 11 ± 10 -
Race (black/white/asian) 20/9/1 10/5/0 30/14/1
PC20 (provocative concentration causing a 20 % drop in FEV1, in mg/ml) 2.4 ± 4.2 2.6 ± 2.1 2.4 ± 3.6
FEV1 (forced expiratory volume in 1-second, in L) 2.7 ± 0.7 2.8 ± 0.8 2.7 ± 0.7
FEV1 % predicted (forced expiratory volume in 1-second) 87 ± 10 % 91 ± 13 % 88 ± 11 %
FVC % predicted (forced vital capacity) 90 ± 12 % 97 ± 15 % 92 ± 13 %
FEV1/FVC 0.80 ± 0.08 0.78 ± 0.01 0.79 ± 0.08
TLC (total lung capacity, in L) 5.0 ± 1.4 5.1 ± 1.2 5.0 ± 1.4
SVC (slow vital capacity, in L) 3.3 ± 1 3.5 ± 0.9 3.4 ± 1.0
FRC (functional residual capacity, in L) 3.0 ± 0.9 3.3 ± 1.5 3.1 ± 1.1
RV (residual volume, in L) 1.7 ± 0.7 1.7 ± 0.8 1.7 ± 0.7
RV/TLC 0.34 ± 0.09 0.33 ± 0.08 0.34 ± 0.09
Diffusing capacity of carbon monoxide (mL/min/mm Hg) 22.5 ± 5.9 22.9 ± 5.4 22.7 ± 5.6
Specific airway resistance, (in kiloPascals · s) 6.1 ± 3.4 6.0 ± 3.4 6.04 ± 3.3
Exhaled nitric oxide (ppb) 10.4 ± 11 6.15 9.1 ± 10